Hepatic Encephalopathy

Emergency Medicine Clinics of North America

Volumn 27, Issue 3, 2009, Pages 401-414

  Eroglu, Yasemen ^a   Byrne, William J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Brain edema; Cancer; Emergency department; Encephalopathy; Liver; Liver failure

Indexed keywords

AMMONIA; BENZODIAZEPINE DERIVATIVE; BENZOIC ACID; FLUMAZENIL; LACTULOSE; MANNITOL; METRONIDAZOLE; NARCOTIC AGENT; NEOMYCIN; ORNITHINE ASPARTATE; PHENYTOIN; PLACEBO; PROPOFOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAXIMIN; SEDATIVE AGENT; TRANQUILIZER; VANCOMYCIN;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ALBUMIN DIALYSIS; BLOATING; BRAIN EDEMA; BRAIN HERNIA; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE TITRATION; EMERGENCY CARE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERNATREMIA; HYPERVENTILATION; INTRACRANIAL HYPERTENSION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTAKE; REVIEW; SEDATION; SEIZURE; TRAVELLER DIARRHEA;

EID: 67651177584     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2009.04.005     Document Type: Review

References (83)

1. Ference P., Lockwood A., Mullen K., et al. Hepatic encephalopathy definition, nomenclature, diagnosis, and qualification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 35 (2002) 716-721
2. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 25 1 (2006) 3-9
3. Smith B.C., and James O.F.W. The failing malignant liver. Gut 42 (1998) 454-459
4. Te H.S., Schiano T.D., Kahaleh M., et al. Fulminant hepatic failure secondary to malignant melanoma: case report and review of literature. Am J Gastroenterol 94 (1999) 262-266
5. Alexopoulou A., Koskinas J., Deitsch M., et al. Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of literature. Tumori 92 4 (2006) 354-357
6. Salmon J.S., Thompson M.A., Arildsen R.C., et al. Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations. Clin Lymphoma Myeloma 6 4 (2006) 273-280
7. Nieto Y., Cagnoni P.J., Bearman S.I., et al. Acute encephalopathy: a new toxicity associated with high dose paclitaxel. Clin Cancer Res 5 3 (1999) 481-486
8. Tanvetyanon T., and Choudhury A.M. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol 171 (2004) 1627
9. Yamamoto T., Kuyama Y., Takeuchi K., et al. Hepatic encephalopathy due to portal venous thrombosis in a patient with pancreatic tumor. Pancreas 26 3 (2003) 313-314
10. Kapoor B.S., Hunter D.W., Greeno E., et al. Hepatic encephalopathy secondary to transtumoral portal venous shunting. Hepatogastroenterology 50 49 (2003) 4-7
11. Kondo H., and Kasahara Y. Prevention of severe hepatic injury by interferon-alfa in chronic active hepatitis lacking HBeAg (mutant strain) in a patient with malignant lymphoma. Cancer 125 (1998) 171-175
12. Shawcross D., and Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 62 (2005) 2295-2304
13. Wright G., and Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol 21 (2007) 95-110
14. Cordoba J., and Blei A. Hepatic encephalopathy. In: Schiff E.R., Sorell M.F., and Maddrey W.C. (Eds). Diseases of liver. 10th edition (2007), Lippincott Williams and Wilkins, Philadelphia 569-599
15. Keiding S., Sorensen M., Bender D., et al. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 43 (2006) 42-50
16. Bhatia V., Singh R., and Acharya S.K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 55 (2006) 98-104
17. Kundra A., Jain A., Banga A., et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 38 (2005) 696-699
18. Shawcross D.L., Davies N.A., Williams R., et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40 (2004) 247-254
19. Amodio P., Montagnese S., Gatta A., et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 19 (2004) 253-267
20. Mattarozzi K., Campi C., Guarino M., et al. Distinguishing between clinical and minimal hepatic encephalopathy on the basis of specific cognitive impairment. Metab Brain Dis 20 (2005) 359-367
21. Weissenborn K., Giewekemeyer K., Heidenreich S., et al. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 20 (2005) 359-367
22. Schomerus H., and Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 16 (2001) 37-41
23. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45 (2007) 549-559
24. Mullen K.D. Pathogenesis, clinical manifestation, and diagnosis of hepatic encephalopathy. Semin Liver Dis 27 Suppl 2 (2007) 3-9
25. Ferenci P. Treatment options for hepatic encephalopathy: a review. Semin Liver Dis 27 Suppl 2 (2007) 10-17
26. Conn H.O. Quantifying the severity of hepatic encephalopathy. In: Conn H.O., and Bircher J. (Eds). Hepatic encephalopathy: syndromes and therapies (1994), Medi-ed Press, Bloomington (IL) 13-26
27. Groeneweg M., Quero J.C., De Bruijn I., et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 28 (1998) 45-49
28. Morgan M.Y. Cerebral magnetic resonance imaging in patients with chronic liver disease. Metab Brain Dis 13 (1998) 273-290
29. Ong J.P., Aggarwal A., Krieger D., et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 114 (2003) 188-193
30. Nicolao F., Efrati C., Masini A., et al. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol 38 (2003) 441-446
31. Kramer L., Tribl B., Gendo A., et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 31 (2003) 30-34
32. Mortensen P.B. The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 16 (1992) 1350-1356
33. Als-Nielsen B., Gluud L.L., and Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328 (2004) 1046
34. Strauss E., Tramote R., Silva E.P., et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39 (1992) 542-545
35. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 72 (1977) 573-583
36. Atterbury C.E., Maddrey W.C., and Conn H.O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 23 (1978) 398-406
37. Blanc P., Daures J.P., Liautard J., et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol 18 (1994) 1063-1068
38. Lizardi-Cervera J., Almeda P., Guevara L., et al. Hepatic encephalopathy: a review. Ann Hepatol 2 3 (2003) 122-130
39. Williams R., and Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, safety. Rev Gastroenterol Disord 5 Suppl 1 (2005) S10-S18
40. Jaing Z.D., Ke S., Palazzini E., et al. In vitro activity and fecal concentration of rifaximin after oral administraton. Antimicrobial Agents Chemother 44 8 (2000) 2205-2206
41. Pedretti G., Calzetti C., Missale G., et al. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 23 (1991) 175-178
42. Bucci L., and Palmieri G.C. Double blind, double dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13 (1993) 109-118
43. Leevy C., and Phillips J. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52 (2007) 737-741
44. Neff G., Kemmer N., Zacharias V., et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 38 (2006) 3552-3555
45. Huang E., Esrailian E., and Spiegel B.M.R. The cost effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 26 (2007) 1147-1161
46. Bass N.M., Ahmed A., Johnson L., et al. Rifaximin treatment is beneficial for mild hepatic encephalopathy. Hepatology 40 suppl 4 (2004) 646A [abstract 1116]
47. Sushma S., Dasarathy S., Tandon R.K., et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double blind randomized trial. Hepatology 16 (1992) 138-144
48. Efrati C., Masini A., Merli M., et al. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 95 12 (2004) 3574-3578
49. Barbaro G., Di Lorenzo G., Soldini M., et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo controlled, cross-over study. Hepatology 28 (1998) 374-378
50. Als-Nielsen B., Kjaergard L.L., and Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 4 (2001) CD002798
51. Goulenok C., Bernard B., Cadranel J.F., et al. Flumezanil vs placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 16 (2002) 361-372
52. Kircheis G., Wettstein M., Dahl S., et al. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 17 (2002) 453-462
53. Stauch S., Kircheis G., Adler G., et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 28 (1998) 856-864
54. Stange J., Mitzner S.R., Klammt S., et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 6 (2000) 603-613
55. Heeman U., Treichel U., Loock J., et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36 (2002) 949-958
56. Cordoba J., Lopez-Hellin J., Planas M., et al. Normal protein diet for episodic hepatic encephalopathy: results of randomized study. J Hepatol 41 (2004) 38-43
57. Vaquero J., Polson J., Chung C., et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 125 (2003) 755-764
58. Bernal W., Hall C., Karvellas C.J., et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 46 6 (2007) 1844-1852
59. Munoz S.J. Difficult management problems in fulminant hepatic failure. Semin Liver Dis 13 (1993) 395-413
60. Clemmesen J.O., Larsen F.S., Kondrup J., et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29 (1999) 648-653
61. Rolando N., Wade J., Davalos M., et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32 (2000) 734-739
62. Wiest R., and Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 41 (2005) 422-433
63. Blei A.T., Olafsson S., Webster S., et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 341 (1993) 157-158
64. Vaquero J., Fontana R.J., Larson A.M., et al. Complications of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 11 (2005) 1581-1589
65. Alba L., Hay J.E., Angulo P., et al. Lactulose therapy in acute liver failures. J Hepatol 36 (2002) 33A
66. Hoofnagle J.H., Carithers R.L., Sapiro C., et al. Fulminant hepatic failure: summary of a workshop. Hepatology 21 (1995) 240-252
67. Donovan J.P., Shaw Jr. B.W., Langnas A.N., et al. Brain water and acute liver failure: the emerging role of intracranial pressure monitoring. Hepatology 16 (1992) 267-268
68. Nath F., and Galbraith S. The effect of mannitol on cerebral white matter water content. J Neurosurg 65 (1986) 41-43
69. Canalese J., Gimson A.E.S., Davis C., et al. Controlled trial of dexamethasone and mannitol for the cerebral edema of fulminant hepatic failure. Gut 23 (1982) 625-629
70. Simma B., Burger R., Falk M., et al. A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer's solution versus hypertonic saline. Crit Care Med 26 (1998) 1265-1270
71. Khanna S., Davis D., Peterson B., et al. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric patients. Crit Care Med 28 (2000) 1144-1151
72. Murphy N., Auzinger G., Bernel W., et al. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 29 2 (2004) 464-470
73. Bernel W., Auzinger G., Sizer E., et al. Intensive care management of acute liver failure. Semin Liver Dis 28 (2008) 188-200
74. Blei A.T. Brain edema in acute liver failure. Crit Care Clin 24 (2008) 99-114
75. Lee W.M., Rossaro L., Fontana R., et al. Intravenous N-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure. Hepatology 46 (2007) 71A
76. Polson J., and Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology 41 5 (2005) 1179-1197
77. Rowbotham D., Wendon J., and Williams R. Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut 42 (1998) 576-580
78. Mas M.R., Sinsek I.C., Can C., et al. Fulminant hepatic failure as the initial presentation of primary hepatocellular carcinoma. Eur J Gastroenterol Hepatol 12 5 (2000) 575-578
79. Kohrt H.E., Ouyang D.L., and Keeffe E.B. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 11 4 (2007) 965-991
80. Wallace M.J., Madoff D.C., Ahrar K., et al. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting. Cancer 101 2 (2004) 337-345
81. Chung W.J., Jang B.K., Park K.S., et al. Effect of transjugular portosystemic shunt for variceal bleeding in hepatocellular carcinoma patients with portal vein thrombosis. Korean J Hepatol 11 2 (2005) 157-163
82. DeLeve L.D. Cancer chemotherapy. In: Kaplowitz N., and DeLeve L.D. (Eds). Drug-induced liver disease (2003), Marcel Dekker, New York 593-632
83. Chan J.S., Harding C.O., and Blanke C.D. Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarboylase (OTC) deficiency. Southampt Med J 101 5 (2008) 543-545